Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00654498
First received: March 27, 2008
Last updated: June 3, 2014
Last verified: March 2014
  Purpose

To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)


Condition Intervention Phase
Restless Legs Syndrome
Drug: Pramipexole
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS). [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    The IRLS was a 10-item self patient's rating scale for assessing severity of restless legs syndrome symptoms with each item ranging from 0 (no symptoms) to 4 (very severe symptoms). The total IRLS score ranges from 0 (no symptoms) to 40 (worst possible symptoms).

  • The Proportion of Patients With Clinical Global Impressions -Improvement Scale (CGI-I) Assessment of "Much Improved" and "Very Much Improved" [ Time Frame: 6 weeks of treatment ] [ Designated as safety issue: No ]
    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved)and 2 (much improved.


Secondary Outcome Measures:
  • The Proportion of IRLS Responders [ Time Frame: 6 weeks of treatment ] [ Designated as safety issue: No ]
    responders is defined as the total score in IRLS changed ≥ 50%from baseline calculated in the full analysis set population.

  • The Proportion of Patient Global Impression(PGI) Responders [ Time Frame: 6 weeks of treatment ] [ Designated as safety issue: No ]
    PGI was a one-question scale with 7 degrees to assess patient's overall condition, ranging from very much better to very much worse. The responder are defined as patients with their assessment of "much better" or "very much better".

  • The Proportion of Patients With Epworth Sleepiness Scale (ESS) Categorised >10 [ Time Frame: week 6 of treatment ] [ Designated as safety issue: No ]
    The ESS is a self-administered instrument to assess the patients likelihood of falling asleep in various activities of daily living; the maximum score is 24 indicating a very high level of daytime sleepiness and a high likelihood of falling asleep.

  • the Mean Change From Baseline to Week 6 in Satisfaction of Sleep at Night of RLS-6 Rating Scales [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    RLS-6 rating scales comprises 6 questions Satisfaction of sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the satisfaction of sleep.

  • The Mean Change From Baseline in the Severity of RLS at Time of Falling Sleep of RLS-6 Rating Scales. [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    RLS-6 rating scales comprises 6 questions. The severity of RLS at time of falling sleep is one of the 6 questions. The patient should give a rate between 0 (none/Not at all) to 10 (very severe) for the severity of RLS at time of falling sleep

  • The Mean Change From Baseline in the Severity of RLS During the Night of RLS-6 Rating Scales. [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    RLS-6 rating scales comprises 6 questions. The severity of RLS during the night is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the night.

  • The Mean Change From Baseline in the Severity of RLS During the Rest at Day of RLS-6 Rating Scales. [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    RLS-6 rating scales comprises 6 questions. The severity of RLS during the test at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the rest at day.

  • The Mean Change From Baseline in the Severity of RLS During the Activities at Day of RLS-6 Rating Scale [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    RLS-6 rating scales comprises 6 questions. The severity of RLS during the activities at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the severity of RLS during the activity at day.

  • The Mean Change From Baseline in the Intensity of Tiredness and Sleepiness at Day of RLS-6 Rating Scale [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    RLS-6 rating scales comprises 6 questions. The intensity of tiredness and sleepiness at day is one of the 6 questions. The patient should give a rate between 0 ("none/Not at all") to 10 ("very severe") for the intensity of tiredness and sleepiness at day.

  • The Change From Baseline in Visual Analogue Scales (VAS) [ Time Frame: Baseline and 6 weeks of treatment ] [ Designated as safety issue: No ]
    VAS is for assessment of RLS-associated pain. The patient was asked "How severe was your RLS associated pain in legs or arms during the past week?". No pain:0; very worst pain:10


Enrollment: 306
Study Start Date: April 2008
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Pramipexole
4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
Drug: Pramipexole
Placebo
4 weeks of individual dose titration as for the investigational product, once daily
Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent consistent with International Conference on Harmonisation (ICH) / Good Clinical Practice (GCP) and local legislation given prior to any study procedures.
  2. Ability and willingness to comply with study treatment regimen and to attend study assessments.
  3. Male or female out-patients aged 18-80 years.
  4. Diagnosis of idiopathic Restless Legs Syndrome (IRLS) according to the clinical Restless Legs Syndrome (RLS) criteria of the International Restless Legs Syndrome Study Group (IRLSSG)

    All four criteria must be present to fulfil the diagnosis of RLS:

    • An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. (Sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs).
    • The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.
    • The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
    • The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).
  5. Restless Legs Syndrome (RLS)rating scale for severity total score >15.
  6. Restless Legs Syndrome (RLS) symptoms present at least 2 to 3 days per week during the last 3 months.

Exclusion Criteria:

  1. Women of child-bearing potential (i.e. premenopausal women, or postmenopausal women less than 2 years after last menses) who do not use during the clinical trial an adequate method of contraception such as: hormonal therapy (combined oral contraceptives, injectables, or subcutaneous implants), hormonal intrauterine devices, sexual abstinence, surgical sterilization of patient and/or partner, hysterectomy, bilateral ovariectomy or partners vasectomy
  2. Any woman of child-bearing potential not having a negative pregnancy test at screening
  3. Patients who are breastfeeding
  4. Concomitant or previous pharmacologically therapy of RLS as follows:

    • Any intake of levodopa within 5 days prior to baseline visit (V2)
    • Any intake of dopamine agonists within 14 days prior to baseline visit (V2)
  5. Current (less than 14 days before treatment with trial medication or concomitant) treatment with medication or dietary supplements, which could significantly influence RLS symptoms, e.g. dopaminergic (other than levodopa or dopamine agonists) or anti-dopaminergic drugs, non-selective Monoamine Oxidase (MAO) inhibitors, sympathomimetics, neuroleptics, anti-depressants, hypnotics, any benzodiazepines, antiepileptics, opioids, clonidine, magnesium, ferrous salts, Folic acid, vitamin B12, antihistaminics, lithium, metoclopramide or Withdrawal symptoms caused by stopping any of the drugs above
  6. Confirmed diagnose of diabetic nephropathy or clinically significant renal disease
  7. Creatinine higher than upper limit of normal (ULN) at screening
  8. Clinical significant hepatic disease or Alanine aminotransferase (ALT) >2 times the upper limit of normal range at screening
  9. Clinical or laboratory signs of microcytic anaemia, or ferritin in serum below the lower bound of the reference range
  10. Any of the following lab results at screening:

    • Basal Thyroid Stimulating Hormone (TSH), T3 or T4 clinically significantly (at the investigators discretion) out of normal range at screening (if not caused by substitution therapy according the investigators opinion)
    • Patients with any clinically significant abnormalities in laboratory parameters at screening at the investigators discretion
  11. Other clinically significant metabolic-endocrine, haematological, gastro-intestinal disease or pulmonary disease (such as severe COPD). Poorly controlled cardiovascular disease (including hypotension and severe coronary artery disease)
  12. History or clinical signs of peripheral neuropathy (PNP) of any origin in physical, neuro-logical examination, myelopathy or multiple sclerosis or any other neurological disease, with potential to secondarily cause RLS symptoms
  13. Presence of any other sleep disorder, such as, Rapid Eye Movement (REM) sleep behaviour disorder, narcolepsy or sleep apnoea syndrome
  14. History of Schizophrenia or any psychotic disorder, history of mental disorders due to a general medical condition or any present axis I psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM IV) requiring any medical therapy
  15. History of alcohol abuse or drug addiction within the last 2 years before screening
  16. Participation in a drug study within two months prior to the start of this study
  17. History of or clinical signs for any form of epilepsy or seizures apart from fever related seizures in early childhood
  18. History of or clinical signs of malign neoplasm
  19. Patients on a shift-work-schedule, or who are otherwise unable to follow a regular sleep-wake cycle enabling use of study medication at times indicated
  20. Any other conditions that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health hazard for the subject
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00654498

Locations
China
248.630.04 Boehringer Ingelheim Investigational Site
Beijing, China
248.630.05 Boehringer Ingelheim Investigational Site
Beijing, China
248.630.06 Boehringer Ingelheim Investigational Site
Beijing, China
248.630.07 Boehringer Ingelheim Investigational Site
Beijing, China
248.630.08 Boehringer Ingelheim Investigational Site
Beijing, China
248.630.15 Boehringer Ingelheim Investigational Site
Guangzhou, China
248.630.14 Boehringer Ingelheim Investigational Site
Haerbin, China
248.630.10 Boehringer Ingelheim Investigational Site
Hangzhou, China
248.630.09 Boehringer Ingelheim Investigational Site
Nanjing, China
248.630.12 Boehringer Ingelheim Investigational Site
Qingdao, China
248.630.01 Boehringer Ingelheim Investigational Site
Shanghai, China
248.630.02 Boehringer Ingelheim Investigational Site
Shanghai, China
248.630.03 Boehringer Ingelheim Investigational Site
Shanghai, China
248.630.16 Boehringer Ingelheim Investigational Site
Suzhou, China
248.630.13 Boehringer Ingelheim Investigational Site
Wuhan, China
248.630.11 Boehringer Ingelheim Investigational Site
Xian, Shanxi Province, China
Sponsors and Collaborators
Boehringer Ingelheim
  More Information

Additional Information:
No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00654498     History of Changes
Other Study ID Numbers: 248.630
Study First Received: March 27, 2008
Results First Received: December 18, 2009
Last Updated: June 3, 2014
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Psychomotor Agitation
Restless Legs Syndrome
Syndrome
Disease
Dyskinesias
Dyssomnias
Mental Disorders
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Parasomnias
Pathologic Processes
Psychomotor Disorders
Signs and Symptoms
Sleep Disorders
Sleep Disorders, Intrinsic
Pramipexole
Anti-Dyskinesia Agents
Antioxidants
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 23, 2014